However, clinical consideration is still required
Why Cardiovascular
Well, I think that's also part of it, right
Side effect risks: Ozempic and Zepbound have a similar side effect profile, including gastrointestinal side effects, injection site reactions, pancreatitis, kidney issues, gallbladder disease, hypoglycemia, and risk of thyroid tumors
In addition to weight reduction, the Phase 2 trial reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in blood pressure Favourable changes in lipid profiles Reductions in fasting glucose and insulin resistance Increases in heart rate were also observed, consistent with findings seen with other incretin-based therapies These findings suggest that retatrutide may offer broader metabolic benefits beyond weight loss alone, which is particularly relevant for patients with obesity-related comorbidities such as type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), or elevated cardiovascular risk
Feeling okay afterward is
